Ubrogepant users' real‐world experience: Patients on ubrogepant, characteristics and outcomes (UNIVERSE) study

• DOI: 10.1111/head.14839
• Publication Date: 2024-09-26T11:56:16Z
• Authors: Anand R. Shewale; Weijie Poh; Michael L. Reed; Jinjie Liu; Francois Cadiou; Ali Ezzati; Kate Burslem; Shivaji Manthena; Richard B. Lipton
• Keywords: Tolerability; Migraine treatment

Abstract Objective To assess the real‐world effectiveness of ubrogepant by evaluating self‐reported satisfaction with pain relief, ability to think clearly, and return normal function in individuals who had used treat a migraine episode within preceding 14 days. Background Ubrogepant is an oral calcitonin gene–related peptide receptor antagonist approved for acute treatment adults. Few studies have evaluated ubrogepant. Methods The UNIVERSE study was observational, cross‐sectional survey conducted between February 2021 April US adult Migraine Buddy application (app) users currently treated Individuals were 18 years age or older reported at least one dose previous days completed 30‐question app. assessed respondent demographics, history, patterns, Respondents also prior medication use reasons switching Results Of 1303 contacted, 302 (23.2%; 50 mg, 120 participants; 100 182 participants) included this study. mean (standard deviation) 41.9 (11.2) years, 90.1% (272/302) female. Satisfaction relief 2, 4, 24 h post‐dose 75.8% (229/302), 83.4% (252/302), 78.5% (237/302) participants, respectively. clearly after taking 85.1% (257/302) 83.8% (253/302) satisfied their function. Furthermore, 90.7% (274/302) participants that they likely continue using migraine. Most ( n = 264 [87%]) due inadequate response treatment. In subgroup, comparable outcomes observed respect Conclusions demonstrated migraine, as evidenced high levels strong indication intent medication.